Quarterly report pursuant to Section 13 or 15(d)

Note 3 - Revenue (Tables)

v3.23.3
Note 3 - Revenue (Tables)
9 Months Ended
Sep. 30, 2023
Notes Tables  
Disaggregation of Revenue [Table Text Block]
   

Three Months Ended September 30,

   

Nine Months Ended September 30,

 
   

2023

   

2022

   

2023

   

2022

 

Seagen

  $ 9,179     $ 155     $ 14,088     $ 3,074  

AstraZeneca

    3,909       4,404       8,399       9,026  

Servier

    3,951       258       3,846       5,223  

Genentech

          553       12,697       2,733  

Boston Pharmaceuticals

    2,481             2,481        

Total Revenue

  $ 19,520     $ 5,370     $ 41,511     $ 20,056  
Revenue From Contract With Customer, Milestone Payments [Table Text Block]
   

Research, Development, Regulatory & Commercial Milestones

   

Sales Milestones

 

Seagen

  $ 759     $ 450  

Servier

    103       95  

Boston Pharmaceuticals

    85       265  

Total potential milestone payments

  $ 947     $ 810